Genetic and Virulence Characteristics of Linezolid and Pretomanid Dual Drug-Resistant Strains Induced from Mycobacterium tuberculosis in vitro

References

• World Health Organization (WHO). Global tuberculosis report 2019. WHO CDS/TB/2019.20. Geneva, Switzerland: World Health Organization; 2019.
   Google Scholar
• Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893–902. doi:10.1056/NEJMoa190181432130813
   PubMed Web of Science ®Google Scholar
• Dawson R, Diacon AH, Everitt D, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet. 2015;385(9979):1738–1747. doi:10.1016/S0140-6736(14)62002-X25795076
   PubMed Web of Science ®Google Scholar
• Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367(16):1508–1518. doi:10.1056/NEJMoa120196423075177
   PubMed Web of Science ®Google Scholar
• Singh R, Manjunatha U, Boshoff HI, et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science. 2008;322(5906):1392–1395. doi:10.1126/science.116457119039139
   PubMed Web of Science ®Google Scholar
• Sotgiu G, Pontali E, Migliori GB. Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios. Eur Respir J. 2015;45(1):25–29. doi:10.1183/09031936.0014501425552734
   PubMed Web of Science ®Google Scholar
• World Health Organization. Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). World Health Organization Document (2018).WHO/CDS/TB/2018.18.
   Google Scholar
• Chiang CY, Van Deun A, Rieder HL. Gatifloxacin for short, effective treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016;20(9):1143–1147. doi:10.5588/ijtld.15.088427510237
   PubMed Web of Science ®Google Scholar
• Ndjeka N, Schnippel K, Master I, et al. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Eur Respir J. 2018;52(6):6. doi:10.1183/13993003.01528-2018
   Web of Science ®Google Scholar
• Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000;405(6789):962–966. doi:10.1038/3501610310879539
   PubMed Web of Science ®Google Scholar
• Haver HL, Chua A, Ghode P, et al. Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015;59(9):5316–5323. doi:10.1128/AAC.00308-1526100695
   PubMed Web of Science ®Google Scholar
• Manjunatha UH, Boshoff H, Dowd CS, et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2006;103(2):431–436. doi:10.1073/pnas.050839210316387854
   PubMed Web of Science ®Google Scholar
• Beckert P, Hillemann D, Kohl TA, et al. rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains. Antimicrob Agents Chemother. 2012;56(5):2743–2745. doi:10.1128/AAC.06227-1122371899
   PubMed Web of Science ®Google Scholar
• Richter E, Rusch-Gerdes S, Hillemann D. First linezolid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2007;51(4):1534–1536. doi:10.1128/AAC.01113-0617242139
   PubMed Web of Science ®Google Scholar
• Zhang Z, Pang Y, Wang Y, Liu C, Zhao Y. Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China. Int J Antimicrob Agents. 2014;43(3):231–235. doi:10.1016/j.ijantimicag.2013.12.00724439458
   PubMed Web of Science ®Google Scholar
• Pang Y, Zong Z, Huo F, et al. In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis in Beijing, China. Antimicrob Agents Chemother. 2017;61(10):10. doi:10.1128/AAC.00900-17
   Web of Science ®Google Scholar
• Bloemberg GV, Keller PM, Stucki D, et al. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. N Engl J Med. 2015;373(20):1986–1988. doi:10.1056/NEJMc150519626559594
   PubMed Web of Science ®Google Scholar
• Zimenkov DV, Nosova EY, Kulagina EV, et al. Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region. J Antimicrob Chemother. 2017;72(7):1901–1906. doi:10.1093/jac/dkx09428387862
   PubMed Web of Science ®Google Scholar
• Gygli SM, Borrell S, Trauner A, Gagneux S. Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives. FEMS Microbiol Rev. 2017;41(3):354–373. doi:10.1093/femsre/fux01128369307
   PubMed Web of Science ®Google Scholar
• Smith KL, Saini D, Bardarov S, et al. Reduced virulence of an extensively drug-resistant outbreak strain of Mycobacterium tuberculosis in a murine model. PLoS One. 2014;9(4):e94953. doi:10.1371/journal.pone.009495324733050
   PubMed Web of Science ®Google Scholar
• De Majumdar S, Sikri K, Ghosh P, et al. Genome analysis identifies a spontaneous nonsense mutation in ppsD leading to attenuation of virulence in laboratory-manipulated Mycobacterium tuberculosis. BMC Genomics. 2019;20(1):129. doi:10.1186/s12864-019-5482-y30755157
   PubMed Web of Science ®Google Scholar
• Smith I. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microbiol Rev. 2003;16(3):463–496. doi:10.1128/CMR.16.3.463-496.200312857778
   PubMed Web of Science ®Google Scholar
• Ismail N, Omar SV, Ismail NA, Peters RPH. In vitro approaches for generation of Mycobacterium tuberculosis mutants resistant to bedaquiline, clofazimine or linezolid and identification of associated genetic variants. J Microbiol Methods. 2018;153:1–9. doi:10.1016/j.mimet.2018.08.01130165087
   PubMed Web of Science ®Google Scholar
• Lu Y, Zheng M, Wang B, et al. Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation. Antimicrob Agents Chemother. 2011;55(11):5185–5193. doi:10.1128/AAC.00699-1121844321
   PubMed Web of Science ®Google Scholar
• Xu J, Wang B, Hu M, et al. Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2017;61(6):6. doi:10.1128/AAC.00239-17
   Web of Science ®Google Scholar
• Zhang S, Chen J, Cui P, et al. Mycobacterium tuberculosis mutations associated with reduced susceptibility to linezolid. Antimicrob Agents Chemother. 2016;60(4):2542–2544. doi:10.1128/AAC.02941-1526810645
   PubMed Web of Science ®Google Scholar
• Feuerriegel S, Koser CU, Bau D, et al. Impact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824. Antimicrob Agents Chemother. 2011;55(12):5718–5722. doi:10.1128/AAC.05500-1121930879
   PubMed Web of Science ®Google Scholar
• Cheng G, Hussain T, Sabir N, et al. Comparative study of the molecular basis of pathogenicity of M. bovis strains in a mouse model. Int J Mol Sci. 2018;20(1):1. doi:10.3390/ijms20010005
   Web of Science ®Google Scholar
• Ordonez AA, Tasneen R, Pokkali S, et al. Mouse model of pulmonary cavitary tuberculosis and expression of matrix metalloproteinase-9. Dis Model Mech. 2016;9(7):779–788. doi:10.1242/dmm.02564327482816
   PubMed Web of Science ®Google Scholar
• Hillemann D, Rusch-Gerdes S, Richter E. In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants. Antimicrob Agents Chemother. 2008;52(2):800–801. doi:10.1128/AAC.01189-0718070973
   PubMed Web of Science ®Google Scholar
• Makafe GG, Cao Y, Tan Y, et al. Role of the Cys154Arg substitution in ribosomal protein L3 in oxazolidinone resistance in mycobacterium tuberculosis. Antimicrob Agents Chemother. 2016;60(5):3202–3206. doi:10.1128/AAC.00152-1626953211
   PubMed Web of Science ®Google Scholar
• Dye C, Espinal MA. Will tuberculosis become resistant to all antibiotics? Proc Biol Sci. 2001;268(1462):45–52. doi:10.1098/rspb.2000.132812123297
   PubMed Web of Science ®Google Scholar
• Koch A, Mizrahi V, Warner DF. The impact of drug resistance on Mycobacterium tuberculosis physiology: what can we learn from rifampicin? Emerg Microbes Infect. 2014;3(3):e17. doi:10.1038/emi.2014.1726038512
   PubMed Web of Science ®Google Scholar
• Besier S, Ludwig A, Zander J, Brade V, Wichelhaus TA. Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances. Antimicrob Agents Chemother. 2008;52(4):1570–1572. doi:10.1128/AAC.01098-0718212098
   PubMed Web of Science ®Google Scholar
• McNeil MB, Dennison DD, Shelton CD, Parish T. In vitro isolation and characterization of oxazolidinone-resistant mycobacterium tuberculosis. Antimicrob Agents Chemother. 2017;61(10):10. doi:10.1128/AAC.01296-17
   Web of Science ®Google Scholar
• Sander P, Belova L, Kidan YG, Pfister P, Mankin AS, Bottger EC. Ribosomal and non-ribosomal resistance to oxazolidinones: species-specific idiosyncrasy of ribosomal alterations. Mol Microbiol. 2002;46(5):1295–1304. doi:10.1046/j.1365-2958.2002.03242.x12453216
   PubMed Web of Science ®Google Scholar
• Montoya-Rosales A, Provvedi R, Torres-Juarez F, et al. lysX gene is differentially expressed among Mycobacterium tuberculosis strains with different levels of virulence. Tuberculosis (Edinb). 2017;106:106–117. doi:10.1016/j.tube.2017.07.00528802397
   PubMed Web of Science ®Google Scholar
• Paolino M, Brindisi M, Vallone A, et al. Development of potent inhibitors of the Mycobacterium tuberculosis virulence factor zmp1 and evaluation of their effect on Mycobacterial survival inside macrophages. ChemMedChem. 2018;13(5):422–430. doi:10.1002/cmdc.20170075929334428
   PubMed Web of Science ®Google Scholar
• Rifat D, Campodonico VL, Tao J, et al. In vitro and in vivo fitness costs associated with Mycobacterium tuberculosis RpoB mutation H526D. Future Microbiol. 2017;12(9):753–765. doi:10.2217/fmb-2017-002228343421
   PubMed Web of Science ®Google Scholar